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Introduction: Nonsurgical adult male circumcision devices pres-
ent an alternative to surgery where health resources are limited. This
study aimed to assess the safety, feasibility, and acceptability of the
PrePex device for adult male circumcision in Malawi.
Methods: A prospective single-arm cohort study was conducted at
3 sites (1 urban static, 1 rural static, 1 rural tent) in Malawi. Adverse
event (AE) outcomes were stratified to include/exclude pain, and
confidence intervals (CIs) were corrected for clinic-level clustering.
Results: Among 935 men screened, 131 (14.0%) were not
eligible, 13 (1.4%) withdrew before placement, and 791 (84.6%)
received the device. Moderate and severe AEs totaled 7.1%
including pain [95% CI: 3.4–14.7] and 4.0% excluding pain
(95% CI: 2.6 to 6.4). Severe AEs included pain (n = 3), insufficient
skin removal (n = 4), and early removal (n = 4). Among early
removals, 1 had immediate surgical circumcision, 1 had surgery
after 48 hours of observation, 1 declined surgery, and 1 did not
return to our site although presented at a nearby clinic. More than
half of men (51.9%) reported odor; however, few (2.2%) stated
they would not recommend the device to others because of odor.
Median levels of reported pain (scale, 1–10) were 2 (interquartile
range, 2–4) during application and removal, and 0 (interquartile
range, 0–2) at all other time points.
Conclusions: Severe AEs were rare and similar to other programs.
Immediate provision of surgical services after displacement or early
removal proved a challenge. Cases of insufficient skin removal were
linked to poor technique, suggesting provider training requires
reinforcement and supervision.
Key Words: voluntary medical male circumcision, HIV prevention,
nonsurgical devices, PrePex
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INTRODUCTION
Voluntary medical male circumcision (VMMC) has
been shown to decrease risk for acquisition of HIV among
heterosexual men by approximately 60%,1–3 prompting
a large-scale effort to expand VMMC services in countries
with low numbers of circumcised men and high HIV
prevalence.4 Malawi, 1 of 14 target countries for circumcision
scale-up, has an estimated HIV prevalence of 12.5%, with
male circumcision prevalence estimated at 20.7%.5 The
Government of Malawi formally adopted its male circumci-
sion policy in 2011 and was expected to complete more than
2 million procedures by the end of 2015. However, by 2012,
Malawi had reached ,2% of this target.6
Countries with limited health infrastructure face a number
of challenges in scaling up VMMC services, including
inadequate financial resources, lack of surgical infrastructure,
and lack of human resource capacity.7 Nonsurgical circumcision
devices present an alternative to surgery, where health infra-
structure and resources are limited.8 PrePex (Circ MedTech),
one of such devices, works by compressing the foreskin with
2 rings to block circulation distally, after which the foreskin
becomes necrotic and is removed after a period of 7 days.
Advantages of the device are that the procedure does not require
injectable anesthesia, suturing, or a sterile setting, and the device
can be safely placed and removed by lower cadre providers.9
Early clinical studies indicated that the PrePex device
had similar adverse event (AE) rates to surgical circumcision;
however, a somewhat longer healing time was docu-
mented.10–12 After the clinical trials, the World Health
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Organization (WHO) prequalified the device for consider-
ation in country HIV prevention programs and recommended
a series of noncomparative field studies in settings of intended
use.13 These field studies aim to aid ministries of health in
deciding whether and how to incorporate the PrePex device
into their national VMMC programs, by assessing imple-
mentation within their local context. This study was the pilot
implementation study for Malawi and aimed to assess the
safety, feasibility, and acceptability of the PrePex device for
adult male circumcision in Malawi.
METHODS
Study Design
A prospective single-arm study was conducted at 3
sites (1 urban static, 1 rural static, 1 rural tent) in Malawi.
Before study start, surgical VMMC providers were trained
in PrePex placements, removal, and clinical care by master
trainers from Rwanda.
Male clients were seen at 6 visits over a period of 42 days.
Devices were placed on day 0, clients returned for a clinical
examination on day 2 or day 4 depending on clinic hours, and
for removal on day 7. Follow-up clinical examinations were
conducted at days 14 and 42, and participants returned for an
in-person survey on day 28. Clients were encouraged to return to
clinic in the event of any concerns or problems.
Population and Setting
Provider participants and male clients were recruited
between April and September 2014 from 3 sites linked to
ongoing clinical services in Malawi: an urban static site in
Lilongwe District, a rural static site in Nsanje District, and a rural
tent site in Mulanje District. The Lilongwe andMulanje programs
offered surgical VMMC services. In Nsanje, VMMC was only
available through the general operating theatre at the district
hospital. The Lilongwe outreach site operated out of a VMMC
clinic located on hospital premises, the Mulanje tent site was
located near a health centre and district hospital and remained in
place for the study duration, and the Nsanje site operated out of
renovated clinic space within the district hospital compound.
Recruitment and Inclusion Criteria
Twelve midlevel providers, 4 from each site, were
trained and enrolled. Provider participants included 1 regis-
tered nurse, 6 clinical officers, 4 nurse midwife technicians,
and 1 medical assistant. All were practicing surgical circum-
cision providers through the ministries of health or non-
government organizations.
In Lilongwe and Mulanje, male clients were recruited
among men voluntarily presenting for surgical circumcision. At
these sites, men were informed about both surgical and PrePex
services and were offered a choice of circumcision approaches.
In Nsanje, study team members conducted outreach with local
stakeholders and village chiefs to raise awareness about male
circumcision for HIV prevention and the study. Eligible men
across all sites were HIV-negative, uncircumcised, age 18–49,
who reported access to a mobile telephone most times of the
day. Exclusion criteria included general medical conditions,
genital anatomic abnormalities, active genital infections, inabil-
ity to fit one of the available PrePex device sizes, and evidence
of partial circumcision or scarification.
Sample Size Calculations
A sample size of 805 males was powered to detect the
occurrence of AEs, estimated from the Rwanda trials at
2%.10,11 Sample size estimation was based on a confidence
interval (CI) of 95%, and a margin of error of 61.5%. To
account for between- site variation and within- site clustering,
a design effect of 2.0 was used. In addition, inflation of 20%
in the sample size was used to account for loss to follow-up.
Data Collection
The study assessed provider outcomes of acceptability
and client outcomes of safety and acceptability. Provider
participants completed 2 surveys, 1 at study midpoint and 1
at study end. Client safety outcomes assessed the proportion of
moderate, severe, and device-related AEs among all place-
ments. Timing, type, relatedness to the procedure, and resolu-
tion of each AE were documented. President’s Emergency Plan
for AIDS Relief (PEPFAR) AE definitions were used, which
determine severity based on the intervention required (mild
require minimal monitoring or hygiene, moderate require
antibiotic medication or suturing, severe require surgical
completion). Relatedness was classified as not related, possibly
related, or definitely related.14 Participants who did not return
for scheduled visits were telephoned and asked to return to
clinic. When clients still wearing the device were unable to be
contacted after 3–5 calls, a study team member visited the
client’s place of residence. Participants with AEs requiring
surgical intervention were offered medical follow-up; however,
they were withdrawn from further surveys and procedures.
Their AE information was included in study outcomes.
Statistical Analysis
Statistical analyses were conducted in Stata version
11.2 (College Station). Proportions of AEs were calculated,
and 95% CIs were generated using generalized linear models
with a Poisson distribution, controlling for clustering at the
facility level. Median and interquartile ranges (IQRs) of
reported visual analogue scale pain scores were calculated for
each time point and presented as box plots where 0 represents
no pain and 10 represents the most pain. AE outcomes were
stratified to include and exclude pain to allow comparison
with previous studies, where pain was not considered an AE.
Device-related events, including displacement and self-
removal or early removal, whereas considered severe events
as a result of the need for surgery, are presented separately.
Ethical Considerations
Ethical approvals were received by the Malawi National
Health Sciences Research Committee (#1129), the Médecins
Sans Frontières Ethics Review Board (#1331), the University
of Washington Institutional Review Board (#45648), and the
US Centers for Disease Control and Prevention (2104-173).
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RESULTS
Screening and Enrollment
Screening outcomes are documented in Figure 1.
Among 935 men screened, 804 were enrolled and 131
(14.0%) were excluded. Reasons for exclusion included
HIV-positive status (n = 15), general medical exclusions
(n = 5), anatomical variations or anomalies of the genitalia
(n = 75), current genitourinary disease or trauma (n = 10),
evidence or partial circumcision or scarification (n = 1), others
(n = 7), multiple reasons (n = 4), or declined to participate
(n = 11). Among 804 enrolled men, 13 (1.6%) withdrew
before device placement. Postenrollment exclusions or with-
drawals included cases where device sizes were too small or
too large (n = 7), the client left or decided not to participate
before placement (n = 4), and difficult placements due to
anatomy (n = 2). Overall, 791 (84.6%) men received the
PrePex device, among whom 780 (98.6%) completed all
study visits. Four patients were withdrawn after early device
removal or displacement, 4 participants were lost to follow-
up, and 3 withdrew after scheduled removal.
Demographics and Sexual Behavior
Most participants were young, with 86.1% under the
age of 30, and represented a diverse mix of ethnic groups
(Table 1). Most participants had education higher than
primary school, 18.3% attended junior secondary, 37.7%
attended senior secondary, and 15.9% had higher than
secondary education. Men were relatively equally distributed
between types of employment involving frequent lifting and
moving (31.9%), mostly desk-based work (27.6%), and
unemployment (34.1%). Most participants (95.3%) self-
identified as Christian. Approximately one-quarter (24.3%)
were married, 34.1% were in a relationship, and 41.2%
reported no current sexual partner. Eighty percent of clients
(n = 636) reported being sexually active. Among the 338 men
who reported recent sexual activity in the last 3 months, 190
(56.2%) reported using a condom.
Safety Outcomes
Safety outcomes are presented in Table 2. There were
56 moderate and severe AEs defined as possibly related and
definitely related to the PrePex procedure, 24 (48.9%) of
which were reported pain. The prevalence of AEs was 7.1%
including pain (95% CI: 3.4 to 14.7) and 4.0% excluding pain
(95% CI: 2.6 to 6.4). There were 53 definitely related events:
6.7% including pain (95% CI: 3.2 to 13.9) and 3.7%
excluding pain (95% CI: 2.4 to 5.6).
Severe AEs included pain (n = 3) and insufficient skin
removal requiring surgical completion (n = 4). There were 4
device-related AEs: 2 early removals occurred on day 0, 1
device displacement occurred on day 1, and 1 device
displacement occurred on day 3. Among the 2 day 0 cases, 1
participant self-removed the device 8.5 hours after placement,
declined surgery, and would not return despite home visits. On
examination at home, the client had no physical problems. The
other did not return to our site but presented at a nearby clinic
without complications. The day 1 displacement presented
immediately and received surgical completion. The day 3
displacement presented more than 8 hours after removal and
had surgery after antibiotic treatment and observation over 48
hours at the direction of the study surgeon.
Three possible events included 2 cases of painful
urination diagnosed by providers as urinary tract infections
and 1 case of hematuria diagnosed as schistosomiasis. No
cases of tetanus, torsion, or excessive skin removal were
found. No occurrences of erectile dysfunction, scarring, or
psychosocial problems were identified. Most participants (n =
731, 93.7%) had documented complete healing, defined as
complete epithelialization, at day 42.
Provider Acceptability
Providers reported relative ease of device placement
and removal. Providers working in the tent site reported that it
was easier to place PrePex than do surgery in the small
treatment area inside the tent. Among all removals, 643
(81.7%) were rated by providers as 1 (the easiest on a scale
FIGURE 1. Screening and enrollment in the Malawi PrePex pilot study.
J Acquir Immune Defic Syndr  Volume 72, Supplement 1, June 1, 2016 Malawi PrePex Pilot
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. www.jaids.com | S51
of 1–5), 46 (5.9%) reported difficulty as a 2 or 3 of 5, and 4
(0.5%) were reported as the highest levels of difficulty as a 4
or 5 of 5. All providers reported PrePex was superior to
surgical circumcision; 7 providers (58.3%) reported PrePex
was “far superior,” and 5 (41.7%) reported PrePex was
somewhat superior.
Participant Acceptability: Pain, Odor,
Satisfaction, and Resumption of Activities
Median levels of reported pain by participants were 2
(IQR, 2–4) during application and removal and 0 (IQR, 0–2)
at all other time points (Fig. 2). Reported pain was highest
during device removal and decreased 15 minutes after
removal. More than half of men (51.9%) reported odor while
the device was in place; however, only 17 (2.2%) stated they
would not recommend the device to others because of odor.
Odor was most commonly reported at day 4 (33.1%) and day
7 (48.7%) visits, compared to 4.9% of day 2 visits.
At each of the 5 follow-up visits, .90% of participants
stated that they were satisfied with the procedure and results,
and .97% reported that they would recommend the device to
others (Table 3). Most reported that abstaining from sex was
easy or very easy, with 1% (n = 8) reporting sexual activity or
masturbation while the device was in place and 26 (3.3%)
reporting sexual activity or masturbation during the recom-
mended 6 weeks of abstinence. One of the displacement cases
occurred after having sex with the device in place; however,
the client was initially reluctant to admit this. Most clients
(n = 580, 73.7%) reported that they took no time off from
work or school after the procedure. Twenty participants
(2.5%) took between 1 and 7 (median 3) days off, and 3
TABLE 1. Characteristics of Men Seeking PrePex VMMC Services in Malawi Pilot Study, 2014
Characteristic Total (N = 791) Urban Static (N = 299) Rural Tent (N = 194) Rural Static (N = 298)
Age, yrs
18–19 304 (38.4) 67 (22.4) 110 (56.7) 127 (42.6)
20–29 377 (47.7) 179 (59.9) 59 (30.4) 139 (46.6)
30–39 85 (10.7) 47 (15.7) 17 (8.8) 21 (7.0)
40–49 18 (2.3) 5 (1.7) 6 (3.1) 7 (2.3)
Ethnicity
Chewa 157 (19.8) 129 (43.1) 11 (5.7) 17 (5.7)
Lomwe 229 (29.0) 38 (12.7) 173 (89.2) 18 (6.0)
Sena 236 (29.8) 10 (3.3) 2 (1.0) 224 (75.2)
Ngoni 81 (10.1) 64 (21.4) 2 (1.0) 15 (5.0)
Other ethnic groups* 88 (11.1) 58 (19.4) 6 (3.1) 24 (8.1)
Education
Did not go to school 4 (0.5) 1 (0.3) 0 (0.0) 3 (1.0)
Attended primary school 218 (27.6) 36 (12.0) 108 (55.7) 74 (24.8)
Attended junior secondary school 145 (18.3) 46 (15.4) 40 (20.6) 59 (19.8)
Attended senior secondary school 298 (37.7) 112 (37.5) 39 (20.1) 147 (49.3)
Tertiary 126 (15.9) 104 (34.8) 7 (3.6) 15 (5.0)
Physical activity at work
Frequent lifting and moving 252 (31.9) 69 (23.1) 47 (24.2) 136 (45.6)
Mostly sitting at a desk 218 (27.6) 57 (19.1) 69 (35.6) 92 (30.9)
Unemployed 270 (34.1) 152 (50.8) 65 (33.5) 53 (17.8)
Religion
Christian 754 (95.3) 292 (97.7) 181 (93.3) 281 (94.3)
Relationship Status
Married 192 (24.3) 56 (18.7) 70 (36.1) 66 (22.2)
Nonmarital relationship 270 (34.1) 143 (47.8) 33 (17.0) 94 (31.5)
No partner 326 (41.2) 100 (33.4) 89 (45.9) 137 (46.0)
Ever had sex 636 (80.4) 239 (79.9) 154 (79.4) 243 (81.5)
Had sex in last 3 mo 334 (42.2) 122 (40.8) 93 (47.9) 119 (39.9)
Used a condom in the last 3 mo (N = 338) 190 (56.2) 79 (64.2) 47 (49.5) 64 (53.3)
Knowledge
Circumcised men cannot get a sexually transmitted
infection
50 (6.3) 9 (3.0) 26 (13.4) 15 (5.0)
Circumcised men cannot get HIV 39 (4.9) 4 (1.3) 25 (12.9) 10 (3.4)
Circumcised men do not need to use condoms 15 (1.9) 0 (0.0) 9 (4.6) 6 (2.0)
*Includes Tumbuka (n = 31), Nyanja (n = 24), Yao (n = 21), Tonga (n = 6), Ngonde (n = 2), Bemba (n = 1), Sukwa (n = 1), immigrant from Kenya (n = 1), and client does not
know (n = 1).
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(0.4%) took more than a week. Seventy participants (8.9%)
reported intentionally timing their procedure with school or
work holidays.
DISCUSSION
This study found a 7.1% prevalence of AEs including
pain associated with the PrePex device for adult male
circumcision in Malawi. Pilot implementation studies from
Uganda and Kenya have reported AEs between 1.9% and
5.9%.15–17 Although our AE rate was higher than the expected
rates of 2.0% seen in the Rwandan trials, some of the
difference can be explained by the recent inclusion of pain in
the AE definitions. Studies from Rwanda12 and Uganda15,16
did not systematically include pain in their definition of
a moderate or severe AE, whereas our study and the study in
Kenya17 did. In 1 study that measured pain but did not include
it in the AE definition, 15.8% reported experiencing pain of 8
or above on the visual analogue scale.15
Excluding pain and including possibly related events,
we found 4.0% AEs. Other explanations for the higher rates
may include the heightened follow-up, with only 8 clients
(1.0%) lost from the study. Our program also involved
secondary review of case report forms and weekly reviews
of all possible events, which may have identified more cases
than in some program settings. Finally, there is some
variability in the literature about what constitutes an AE
versus an expected side effect. The Rwanda field study listed
cases of oozing, localized edema, and clear exudate as
expected side effects, with 14.6% of clients experiencing
these events.12 In our study, edema was classified as an AE
(we had 3 moderate cases), and oozing or exudate may have
been attributed (correctly or incorrectly) to infection.
Our findings of 4 (0.5%) device displacements and 7
severe events (0.9%) were less than or similar to those of other
PrePex pilot field studies. Displacements in Uganda ranged
between 0.7% and 2.0%15,16 and were 1.2% in Kenya.17 Our
second most common severe event was 4 cases (0.5%) of
insufficient skin removal, compared to no cases in the Uganda
studies and 9 cases (2.1%) in Kenya. During a training visit,
the master trainer suggested that the insufficient skin removals
seemed to be associated with provider placement skills. There
were no further insufficient skin removal events after a refresher
training on proper placement.
The most common moderate AEs, other than pain,
included infection (n = 7, 0.9%) and postremoval bleeding
FIGURE 2. Median pain scores at study visits. Pain scores were reported using a visual analogue scale, where 0 was no pain and 10
was the highest. Scores are presented as box plots, where the boxes represent the IQR, square markers represent the median,
whiskers represent values outside the IQR 6 1.5*IQR from the median, and circle markers represent values outside the whiskers.
Indicators where the high and low values of the IQR are equal to the median value do not have a box.
TABLE 2. Safety—Frequency, Type, Severity, and Timing of










Pain 21 (2.7) 3 (0.4) — 24 (3.0)
Bleeding 10 (1.3) — — 10 (1.3)
Infection 7 (0.9) — — 7 (0.9)
Insufficient skin
removed
— 4 (0.5) — 4 (0.5)
Early removal — — 4 (0.5) 4 (0.5)
Swelling 3 (0.4) — — 3 (0.4)
Dysuria 2 (0.3) — — 2 (0.3)
Wound
dehiscence
1 (0.1) — — 1 (0.1)
Hematuria 1 (0.1) — — 1 (0.1)
Timing of AE
During placement — — —
In situ 10 (1.3) — 4 (0.5) 14 (1.8)
During removal 6 (0.8) 3 (0.4) — 9 (1.1)
After removal 29 (3.7) 4 (0.5) — 33 (4.2)
Related to
Circumcision
Possibly related 3 (0.4) — — 3 (0.4)
Related 42 (5.3) 7 (0.9) 4 (0.5) 53 (6.7)
Total 45 (5.7) 7 (0.9) 4 (0.5) 56 (7.1)
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(n = 10, 1.3%). Providers noted some of these clients had
difficulties with hygiene or applied traditional poultices,
which may have contributed to topical infections. These
cases also could have been misclassification of normal
sloughing, which can have an appearance similar to pus.
Eight of the 10 bleeding cases were clustered over 4 weeks at
a single site. Although we reviewed each case, we could not
identify a cause for this cluster of bleeding events. This may
have been related to provider skill in cutting the elastic band
at removal. In several cases, clients reported picking away
scabs or exudate, which led to bleeding events.
The primary challenges were in management of displace-
ments or early removals. Among early removal cases, 1
participant returned and had immediate surgical circumcision,
1 presented more than 8 hours after removal and had surgery
after antibiotic treatment and observation, 1 declined surgery
even after home visitation, and 1 did not return to our site at all.
Therefore, only one of the 4 displacement clients was able to
successfully access care within the recommended window of 6
hours after presentation to clinic. Access to surgical care within
this window is challenging for rural settings. In 2008, Malawi
had only 0.02 physicians per 1000 individuals, and these are
largely concentrated in city centers. As a result, Malawi would
likely not be able to comply with new general thinking that the
complicated anatomy post-displacement requires advanced
surgical skills. If surgical response could include any trained
surgical VMMC provider, the scale-up of PrePex in Malawi
would be more feasible. Furthermore, although we were able to
verify that they had no further complications, the 2 early
removal cases where participants refused surgery or did not
return are concerning, considering the extensive patient
education provided as part of this study.
There is some debate about whether immediate surgery
after early removal is appropriate in all cases. In 1 case, the
surgeon opted to treat with oral antibiotics and observe the
participant for 48 hours after presentation as there was
concern in performing surgery with the level of edema
present. After 48 hours, the participant had reduced swelling
and the team was able to perform the circumcision without
difficulty. There may be need for additional research to
determine whether delaying surgery may be appropriate in
some cases and may allow nonsurgeons to safely perform the
procedure after swelling has subsided.
Although our study identified no cases of tetanus, there
is also concern over recent reports of 8 cases associated with
VMMC in other countries.18 If programs must provide or
confirm tetanus vaccination, this additional regimen of clinic
visits may further complicate implementation. Additionally,
use of traditional poultices pose risk for contamination with
Clostridium tenani; therefore, it will be important for
clinicians to strongly counsel about proper hygiene and the
healing process.
Although there has been concern about odor, less than
3% of clients reported that this issue would prevent them from
recommending the procedures to others. Clients reported little
difficulty with abstinence; however, we found that clients were
reluctant to admit to sexual activity. Therefore, the proportion of
clients reporting abstinence may be an overestimate. Counseling
on abstaining while the device is in place and safe resumption
of sexual activity will be imperative for all programs.
TABLE 3. Client Acceptability and Satisfaction With the PrePex Device in Malawi
N (%) N (%) N (%)
Satisfaction with PrePex and procedures Somewhat/very satisfied Neither satisfied nor dissatisfied Somewhat/very dissatisfied
After device placement (day 0), N = 791 777 (98.2) 7 (0.9) 4 (0.5)
After device removal (day 7), N = 787 776 (98.6) 4 (0.5) 4 (0.5)
During healing process (day 14), N = 785 728 (92.7) 32 (4.1) 13 (1.7)
During healing process (day 28), N = 782 735 (94.0) 41 (5.2) 2 (0.3)
At end of healing (day 42), N = 780 767 (98.3) 7 (0.9) 3 (0.4)
Would recommend the device to others Yes Neutral No
After device placement (day 0), N = 791 777 (98.2) — 6 (0.8)
While wearing the device (day 2), N = 788 777 (98.6) — 6 (0.8)
After device removal (day 7), N = 787 779 (99.0) — 3 (0.4)
At end of healing (day 42), N = 780 759 (97.3) 12 (1.2) 2 (0.3)
Reported having sex or masturbating Yes — No
While wearing the device (day 2/4), N = 788 8 (1.0) — 772 (98.0)
After device removal (day 7), N = 787 0 (0.0) — 783 (99.5)
During healing process (day 14), N = 785 3 (0.4) — 775 (98.7)
During healing process (day 28), N = 782 5 (0.6) — 772 (98.7)
At last visit (day 42), N = 780 11 (1.4) — 760 (97.4)
At any time during study participation, N = 791 26 (3.3) — 765 (96.7)
Experience abstaining from sex masturbation Easy/very easy Neither easy nor difficult Difficult/very difficult
While wearing the device (day 2), N = 788 719 (91.2) 5 (0.6) 60 (7.6)
After device removal (day 7), N = 787 727 (92.4) 9 (1.1) 47 (6.0)
During healing process (day 14), N = 785 732 (93.3) 2 (0.3) 48 (6.1)
During healing process (day 29), N = 782 720 (92.1) 9 (1.2) 47 (6.0)
At end of healing (day 42), N = 780 727 (93.6) 9 (1.2) 32 (4.1)
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Strengths of this study include little loss to follow-up
and careful review of all possible events. Limitations include
the withdrawal of clients from final satisfaction surveys, AEs
requiring surgical circumcision and limitations in generaliz-
ability to the general male population of Malawi. Compared
to the 2010 Demographic and Health Survey in Malawi, our
participants had more education.19
In conclusion, the PrePex device for male circumcision
can be safely implemented in a variety of settings in Malawi.
However, there are challenges with this approach. The
occurrence of rare but serious events is worrisome in the
context of limited access to surgical facilities and surgical
staff, the very settings where the device would also have the
most immediate benefit. Training will need to be reinforced
through routine supervision; and clients must be counseled
appropriately in hygiene, abstinence, postplacement care, and
timely presentation to clinic in the event of a displacement.
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